IQVIA

1985: By 1985, Quintiles, Inc. had arranged to provide contract services worth millions of dollars to a number of large pharmaceutical firms in the United States.

1987: In January 1987, Quintiles Ltd. began operations to serve clients in the United Kingdom.

1988: In 1988, the company opened an office in Cambridge, Massachusetts to provide contract services to pharmaceutical and biotechnology firms located in the northeastern section of the United States.

1990: In August 1990, Quintiles Pacific, Inc. was established to provide contract services for the biotechnological and pharmaceutical firms in the western United States and around the Pacific Rim.

1991: In 1991, Quintiles GmbH was established in Germany to augment the company's contract services to European clients, and Quintiles Laboratories, Ltd. was created in Atlanta, Georgia to provide contract clinical trial laboratory services to companies that were developing healthcare products.

1996: Continuing its frenetic pace of growth and expansion, in 1996 the company opened offices in Pretoria, South Africa, Vienna, Austria, Helsinki, Finland, Madrid, Spain, and Buenos Aires, Argentina.

1997: Quintiles announced in February 1997 that it had become a publicly traded company.

1999: 1999: Company joins the S&P 500 Index.

2000: Quintiles realigned its operating units, early in 2000, due to recent changes in the development of drugs and the introduction of new medicines; and their impacts to the healthcare industry.

2002: In early 2002, Quintiles bought certain assets of Bioglan Pharma Inc., the United States subsidiary of U.K.-based Bioglan Pharma Plc.

2004: In the first six months of 2004, Quintiles saw an increase of almost a billion dollars in new business.

2015: The acquisition has helped IQVIA grow after-tax operating profit (NOPAT) by 39%, from $495 million in 2015 to $687 million over the past twelve months.

2018: Revenue grew 9% year over year in Q1 2018, and the company’s R&D backlog increased 57%.

1985: By 1985, Quintiles, Inc. had arranged to provide contract services worth millions of dollars to a number of large pharmaceutical firms in the United States.

1987: In January 1987, Quintiles Ltd. began operations to serve clients in the United Kingdom.

1990: In August 1990, Quintiles Pacific, Inc. was established to provide contract services for the biotechnological and pharmaceutical firms in the western United States and around the Pacific Rim.

1997: Quintiles announced in February 1997 that it had become a publicly traded company.

1999: 1999: Company joins the S&P 500 Index.

2000: Quintiles realigned its operating units, early in 2000, due to recent changes in the development of drugs and the introduction of new medicines; and their impacts to the healthcare industry.

2002: In early 2002, Quintiles bought certain assets of Bioglan Pharma Inc., the United States subsidiary of U.K.-based Bioglan Pharma Plc.

2004: In the first six months of 2004, Quintiles saw an increase of almost a billion dollars in new business.

2015: The acquisition has helped IQVIA grow after-tax operating profit (NOPAT) by 39%, from $495 million in 2015 to $687 million over the past twelve months.

2018: Revenue grew 9% year over year in Q1 2018, and the company’s R&D backlog increased 57%.

IQVIA

Share

Contacts

Follow Us

IQVIA

Share

Contacts

Follow Us